health π¬ Big study shows how real data can boost drug labels
A cross-trial synthesis analyzed data from 38,753 participants across nine heart failure trials. Researchers pooled individual data to see short-term effects of combination heart failure therapies on key metrics. The study found that SGLT2 inhibitor combinations slightly reduced kidney function initially, then stabilized. This offers a replicable model for label expansion without needing new RCTs, fitting FDA guidelines. Sponsors can use this template to support labeling changes for HFrEF programs. π